Share on StockTwits

Cell Therapeutics (NASDAQ:CTIC) announced its earnings results on Tuesday. The company reported ($0.20) EPS for the quarter, American Banking News reports. The company had revenue of $1.40 million for the quarter, compared to the consensus estimate of $1.10 million.

On a related note, analysts at WallachBeth Capital initiated coverage on shares of Cell Therapeutics in a research note on Wednesday, March 19th. They set a “hold” rating and a $4.50 price target on the stock.

Cell Therapeutics (NASDAQ:CTIC) traded up 1.66% on Tuesday, hitting $3.07. 3,039,791 shares of the company’s stock traded hands. Cell Therapeutics has a 1-year low of $0.97 and a 1-year high of $4.25. The stock has a 50-day moving average of $3.43 and a 200-day moving average of $2.74. The company’s market cap is $432.3 million.

Cell Therapeutics, Inc develops, acquires and commercializes treatments for cancer. It focuses on building a biopharmaceutical company with a diversified portfolio of oncology drugs.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.